CTOs on the Move

Progyny

www.progyny.com

 
Progyny is a transformative fertility, family building, and women`s health benefits solution, trusted by the nation`s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women`s health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.progyny.com
  • 1359 Broadway 2nd Floor
    New York, NY USA 10018
  • Phone: 212.888.3124

Executives

Name Title Contact Details
Melissa Cummings
Executive Vice President, Chief Operating Officer Profile
Steven Leist
Chief Technology Officer Profile
Caleb O'Connell
Chief Information Security Officer Profile

Similar Companies

CINDE Journal

CINDE Journal is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

H and R Healthcare Inc

H and R Healthcare Inc is a Lakewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evommune

Evommune is a clinical stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases. We are leveraging our innovative, tissue-based approach to advance insights and accelerate the development of these transformative therapies. Evommune is led by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.

Mo Bio Labs

Mo Bio Labs is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mesoblast

Mesoblast is a world leader in developing innovative cellular medicines. We have established what we believe is the industry`s most clinically advanced and diverse portfolio of cell-based products with five programs, two of which are partnered, in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. All our clinical programs target significant, under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.